Abstract
Aims: Canagliflozin was recently approved in type 2 diabetes mellitus (T2DM) patients ≥10 and 24h ) and maximum drug concentration were comparable between paediatric patients and adults for canagliflozin 100‐ or 300‐mg QD. Simulated steady‐state AUC 24h was similar between QD and BID dosing for the same canagliflozin total daily dose in paediatric patients and adults with T2DM. QD to BID bridging was supported by simulated HbA1c and change from baseline in HbA1c in paediatric patients. Conclusions: No canagliflozin dose adjustments are required alone or in combination with metformin to ensure similar plasma exposures between paediatric and adult patients with T2DM, as well as similar HbA1c lowering between QD and BID dosing in paediatric patients.
Funding Information
  • Johnson and Johnson

This publication has 10 references indexed in Scilit: